Other analysts also recently issued reports about the company. Deutsche Bank restated a buy rating on shares of Qiagen in a report on Friday, July 26th. Exane BNP Paribas upgraded shares of Qiagen from a neutral rating to an outperform rating in a report on Friday, July 12th. Barclays boosted their target price on shares of Qiagen from $43.00 to $45.00 and gave the stock an overweight rating in a report on Friday, June 21st. Zacks Investment Research downgraded shares of Qiagen from a hold rating to a sell rating and set a $38.00 target price for the company. in a report on Tuesday, August 6th. Finally, DZ Bank reiterated a neutral rating on shares of Qiagen in a report on Wednesday, July 24th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have issued a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus price target of $41.67.
QGEN stock opened at $34.56 on Tuesday. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.77 and a quick ratio of 1.59. The business has a 50-day moving average price of $37.84 and a 200 day moving average price of $38.73. The company has a market capitalization of $7.85 billion, a P/E ratio of 25.79, a PEG ratio of 2.13 and a beta of 0.83. Qiagen has a 1-year low of $32.33 and a 1-year high of $41.55.
Institutional investors have recently made changes to their positions in the business. Campbell & CO Investment Adviser LLC bought a new position in Qiagen in the first quarter worth about $229,000. PNC Financial Services Group Inc. raised its holdings in Qiagen by 1.8% in the first quarter. PNC Financial Services Group Inc. now owns 205,337 shares of the company’s stock worth $8,353,000 after purchasing an additional 3,609 shares in the last quarter. Cornerstone Advisors Inc. purchased a new stake in shares of Qiagen during the first quarter worth about $44,000. Martingale Asset Management L P grew its stake in shares of Qiagen by 2,044.8% during the first quarter. Martingale Asset Management L P now owns 494,619 shares of the company’s stock worth $20,122,000 after acquiring an additional 471,558 shares during the last quarter. Finally, NumerixS Investment Technologies Inc purchased a new stake in shares of Qiagen during the first quarter worth about $434,000. Institutional investors and hedge funds own 65.04% of the company’s stock.
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Featured Story: Different Options Trading Strategies
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.